DexCom에 대한 매도 수량은 투자자에게 DexCom의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

DexCom (NASDAQ:DXCM) 주식, 공매도 수량 보고

DexCom

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.

News

Hedge Funds

Movers

ALAB

CPNG

DXCM

FLUT

GOOGL

MSFT

TTWO

억만장자 투자자 체이스 콜먼(Chase Coleman)의 헤지펀드인 타이거 글로벌 매니지먼트가 최신 양식 13F를 목요일에 제출하고 이전 분기의 거래 활동을 공개했다. 타이거 글로벌의 포트폴리오 변화를 살펴보겠다.

타이거 글로벌 헤지펀드가 플러터 엔터테인먼트 주식을 매수하고 덱스콤을 매도

Earnings

Management

After-Hours Center

덱스콤(NASDAQ:DXCM)은 목요일 시장 마감 후 제3분기 실적을 발표했다. 이 발표로 주가는 시간외 거래에서 3% 이상 하락했다. 다음은 보고서의 세부 사항이다.

덱스콤의 주식은 긍정적인 3분기 실적 발표에도 시간외 거래에서 3% 이상 하락

Equities

Large Cap

Mid Cap

Broad U.S. Equity ETFs

Small Cap

Econ #s

Federal Reserve

Tech

ETFs

AVGO

MRNA

NVDA

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PODD

XLRE

지난 8 거래일 연속 상승 이후 월스트리트는 잠시 멈췄다. S&amp;P 500과 나스닥 100 지수는 화요일 소폭 하락 마감하여, 각각 2024년 5월과 2023년 10월 이후의 최고의 상승 행진을 멈췄다.

S&amp;P 500, 나스닥 100은 8일 연속 상승 후 소폭 하락 마감: 화요일에 월가의 하락 요인은?

DexCom Inc

Investors with a lot of money to spend have taken a bearish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $139,269, and 8 are calls, for a total amount of $460,585.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $55.0 to $95.0 for DexCom over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 2165.5, with a total volume reaching 2,631.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $55.0 to $95.0, throughout the last 30 days.
<h3>DexCom Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736186430_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.7</td>
<td>$14.4</td>
<td>$14.4</td>
<td>$75.00</td>
<td>$109.4K</td>
<td>159</td>
<td align="right">76</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$3.6</td>
<td>$3.4</td>
<td>$3.6</td>
<td>$80.00</td>
<td>$82.1K</td>
<td>10.4K</td>
<td align="right">281</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.9</td>
<td>$2.75</td>
<td>$2.8</td>
<td>$82.00</td>
<td>$77.2K</td>
<td>99</td>
<td align="right">576</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.3</td>
<td>$82.00</td>
<td>$60.0K</td>
<td>99</td>
<td align="right">826</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.0</td>
<td>$1.95</td>
<td>$1.95</td>
<td>$77.00</td>
<td>$51.8K</td>
<td>19</td>
<td align="right">513</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
In light of the recent options history for DexCom, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>DexCom's Current Market Status</h3>
<ul>
<li>Trading volume stands at 1,506,236, with DXCM's price down by -0.53%, positioned at $80.64.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 31 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $94.66666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Canaccord Genuity continues to hold a Buy rating for DexCom, targeting a price of $99. 
&#x2A; Consistent in their evaluation, an analyst from Citigroup keeps a Buy rating on DexCom with a target price of $91. 
&#x2A; Maintaining their stance, an analyst from Wells Fargo continues to hold a Overweight rating for DexCom, targeting a price of $94. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Decoding DexCom's Options Activity: What's the Big Picture?

Financial giants have made a conspicuous bearish move on DexCom. Our analysis of options history for DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) revealed 8 unusual trades.
Delving into the details, we found 37% of traders were bullish, while 62% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $120,660, and 5 were calls, valued at $426,440.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $75.0 and $100.0 for DexCom, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of DexCom stands at 701.83, with a total volume reaching 1,211.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $75.0 to $100.0, throughout the last 30 days.
<h3>DexCom Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735576230_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.6</td>
<td>$6.5</td>
<td>$6.5</td>
<td>$80.00</td>
<td>$135.2K</td>
<td>2.5K</td>
<td align="right">234</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$6.7</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$80.00</td>
<td>$130.0K</td>
<td>2.5K</td>
<td align="right">316</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$2.95</td>
<td>$2.75</td>
<td>$2.95</td>
<td>$76.00</td>
<td>$59.0K</td>
<td>98</td>
<td align="right">202</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$15.5</td>
<td>$15.2</td>
<td>$15.2</td>
<td>$80.00</td>
<td>$56.2K</td>
<td>790</td>
<td align="right">40</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$8.3</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$75.00</td>
<td>$54.2K</td>
<td>38</td>
<td align="right">67</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
In light of the recent options history for DexCom, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>Currently trading with a volume of 518,458, the DXCM's price is down by -3.01%, now at $77.82. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 38 days.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $94.66666666666667.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Citigroup has decided to maintain their Buy rating on DexCom, which currently sits at a price target of $91. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on DexCom with a target price of $94. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on DexCom with a target price of $99. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Smart Money Is Betting Big In DXCM Options

<a href="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom" title="https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom">https://abbott.mediaroom.com/Abbott-Agrees-to-Global-Continuous-Glucose-Monitoring-Litigation-Settlement-with-Dexcom</a>

Biotech

General

Abbott And DexCom Settle Global Patent Disputes Over Continuous Glucose Monitoring Products; Agreement Dismisses All Cases And Includes 10-Year Non-Litigation Provision With No Financial Payments

Macro Economic Events

Macro Notification

Market Summary

Economics

TNDM

Benzinga Market Summary: S&P Rises On PCE Data, Novo Nordisk Falls On Weight Loss Data, Diabetes Stocks Rise

WIIM

Shares of glucose monitoring stocks are trading higher following weaker-than-expected weight loss data from Novo Nordisk.

<ul>
<li>Dexcom builds on its history of first-in-market innovations with the launch of its new groundbreaking GenAI platform</li>
<li>Dexcom GenAI-enabled technology will leverage Google Cloud's Vertex AI platform and Gemini models and will initially enhance Stelo's Weekly Insights feature by providing users with more personalized content based on glucose levels, activity and sleep</li>
<li>Proprietary platform lays foundation for future GenAI advancements across the Dexcom product portfolio that will further empower its millions of users to help take control of their health</li>
<li>Dexcom to speak on the future of health AI at CES 2025</li>
</ul>

Dexcom Launched Proprietary Generative AI Platform To Integrate GenAI Into Glucose Biosensing

DexCom's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NYSE">DXCM</a>) short percent of float has fallen 7.58% since its last report. The company recently reported that it has 8.42 million shares sold short, which is 2.44% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.38 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>DexCom Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1734367523_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for DexCom has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing DexCom's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, DexCom's peer group average for short interest as a percentage of float is 3.83%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into DexCom's Recent Short Interest

Citigroup analyst Joanne Wuensch maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $85 to $91.

Price Target

Analyst Ratings

Citigroup Maintains Buy on DexCom, Raises Price Target to $91

Wells Fargo analyst Larry Biegelsen maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Overweight and raises the price target from $90 to $94.

Wells Fargo Maintains Overweight on DexCom, Raises Price Target to $94

Watching Shares Of DexCom; Traders Circulating Note American Diabetes Association Updates Standards To Recommend Continuous Glucose Monitoring For Non-Insulin Type 2 Diabetes Patients, Paving Way For Broader Coverage And Market Growth; Bank Of America Reiterates Buy Rating On Dexcom Highlighting Long-Term Earnings Potential

DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for DexCom, presenting an average target of $98.44, a high estimate of $120.00, and a low estimate of $85.00. Highlighting a 1.12% decrease, the current average has fallen from the previous average price target of $99.56. 
<img src="https://www.benzinga.com/files/images/story/2024/1733770860_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of DexCom by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$99.00</td>
<td>$89.00</td>
</tr>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to DexCom. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of DexCom's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of DexCom's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>All You Need to Know About DexCom</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>A Deep Dive into DexCom's Financials</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: DexCom's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 1.97%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 13.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): DexCom's ROE excels beyond industry benchmarks, reaching 6.1%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): DexCom's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 2.05%, the company may face hurdles in achieving optimal financial performance.
Debt Management: DexCom's debt-to-equity ratio stands notably higher than the industry average, reaching 1.31. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Key Takeaways From DexCom Analyst Ratings

Canaccord Genuity analyst William Plovanic maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Buy and raises the price target from $89 to $99.

Canaccord Genuity Maintains Buy on DexCom, Raises Price Target to $99

Last year, Morgan Stanley upgraded its outlook for the U.S. MedTech sector to &#8220;Attractive,&#8221; believing the concerns around GLP-1s were already reflected in stock prices and that fundamentals were strong.
However, this view didn&#8217;t play out as expected, mainly due to unforeseen, company-specific issues, such as DexCom, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) unexpected <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39988466/dexcom-faces-short-term-challenges-but-market-growth-prospects-remain-strong-analys" rel="noreferrer noopener">Q2 channel mix challenges</a>, Edwards Lifesciences Corporation&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39967649/edwards-lifesciences-stock-tumbles-highlights-slowdown-in-tavr-business" rel="noreferrer noopener">slowdown in TAVR procedures</a>, TransMedics Group, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41608129/organ-transplant-medtech-transmedics-q3-performance-disappoints-analyst-outlines-in" rel="noreferrer noopener">seasonal impacts</a>, and iRhythm Technologies, Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41462205/with-fda-approval-irhythm-may-be-able-to-lift-regulatory-overhang-investor-skeptici" rel="noreferrer noopener">DOJ investigation</a>.
Morgan Stanley is bullish on the MedTech industry as volumes and pipelines continue to be strong into 2025 despite a shakey 2024.
The analyst also adds that MedTech seems less exposed to potential delays from extended FDA regulatory pathways than other healthcare sectors, given its lower reliance on PMAs and clinical-trial-heavy products.
The analyst adds that while single-stock surprises are inevitable, the overall outlook for the sector heading into 2025 remains favorable.
Morgan Stanley upgraded the outlook on Intuitive Surgical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) and Stryker Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), moving both to Overweight from Equal-weight, citing:
<ul>
<li>ISRG: Strong demand for the Da Vinci Dv5 system is expected to exceed market expectations for <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41406234/intuitive-surgical-posts-q3-earnings-beat-these-analysts-raise-forecasts-on-dv5-upt" target="_blank" rel="noreferrer noopener">installed base growth</a>.</li>
<li>SYK: While orthopedic procedure volumes face some uncertainty, an estimated $1 billion—$2 billion backlog could drive growth in 2025. The company also benefits from ongoing M&amp;A opportunities <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/40819730/stryker-unveils-new-foot-ankle-solutions-with-truss-implants-details" target="_blank" rel="noreferrer noopener">and product innovations</a>.</li>
</ul>
Additional updates:
<ul>
<li>Procept BioRobotics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>): Initiated at Overweight, driven by increasing demand and higher pricing for Hydros in operating room efficiency, particularly in <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41583831/surgical-robotics-provider-procept-biorobotics-q3-earnings-beats-street-view-analys" target="_blank" rel="noreferrer noopener">lower-volume BPH centers</a>.</li>
<li>Tandem Diabetes Care Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>): Upgraded to Overweight with a $45 price target, as its valuation (below 2x sales) seems overly compressed. Expansion into type 2 diabetes in 2025 could double its <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">total addressable market</a>.</li>
<li>Globus Medical Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>): Upgraded to Overweight with a $100 price target as merger concerns ease and strong above-market growth persists.</li>
<li>Embecta Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>): Raised to Equal-weight from Underweight, factoring in the discontinuation of certain risks and potential upside from GLP-1 <a href="https://www.benzinga.com/news/24/10/41148635/tandem-diabetes-insulin-pump-demand-to-surge-despite-popular-demand-of-weight-loss-drugs-bullish-ana" target="_blank" rel="noreferrer noopener">pen needle demand</a>.</li>
</ul>
The analyst is more cautious about Glaukos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), downgrading it to Underweight from Equal-weight. The analyst notes that iDose is a strong product with promising long-term potential, but the current valuation limits the upside compared to other stocks. Additionally, although the pipeline includes exciting projects like Wet AMD, they remain <a target="_blank" href="https://www.benzinga.com/news/earnings/24/11/41752463/glaukos-reports-30-boost-in-glaucoma-sales-improved-margins-in-q3-analyst-highlights-certain-headwi" rel="noreferrer noopener">years away from fruition</a>.
Morgan Stanley has downgraded Nevro Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVRO#NYSE">NVRO</a>) to Underweight from Equal-weight. Despite trading near record lows, the analyst expects weak demand for spinal cord stimulation devices to persist, with limited <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41910770/why-medical-device-firm-nevro-stock-is-trading-higher-on-tuesday" rel="noreferrer noopener">opportunities for cost reductions</a>.
The analyst remains cautious about STAAR Surgical Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAA#NASDAQ">STAA</a>). While the company is executing well, it faces tough conditions in the refractive surgery market, particularly in China and the U.S.
Lastly, Morgan Stanley is cautious about Baxter International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAX#NYSE">BAX</a>) because it offers fewer upside opportunities than peers and has a more conservative outlook <a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook" rel="noreferrer noopener">on operating margins</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/12/42270388/marvell-and-aws-deepen-collaboration-on-cloud-and-ai-solutions-driving-stock-surge-ahead-of-q3-earnings" target="_blank" rel="noreferrer noopener">Marvell And AWS Deepen Collaboration On Cloud And AI Solutions: Details</a></li>
</ul>
Photo by metamorworks via Shutterstock

Analyst Color

Upgrades

Downgrades

Health Care

EMBC

GKOS

GMED

IRTC

ISRG

NVRO

PRCT

STAA

TMDX

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos

Partnership will enable two-way data flow between Dexcom glucose biosensors and apps and Oura Ring and the Oura App, providing a first-of-its-kind metabolic health management experience.

DexCom, ŌURA Enter Strategic Partnership; Dexcom Is Investing $75M In Ōura Series D Funding

Investors with a lot of money to spend have taken a bearish stance on DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with DXCM, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for DexCom.
This isn't normal.
The overall sentiment of these big-money traders is split between 27% bullish and 45%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $232,705, and 6 are calls, for a total amount of $264,821.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $75.0 to $95.0 for DexCom over the recent three months. 
<h3>Volume &amp; Open Interest Development</h3>
In today's trading context, the average open interest for options of DexCom stands at 671.0, with a total volume reaching 1,728.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in DexCom, situated within the strike price corridor from $75.0 to $95.0, throughout the last 30 days.
<h3>DexCom Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731960018_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$21.6</td>
<td>$21.1</td>
<td>$21.3</td>
<td>$90.00</td>
<td>$95.8K</td>
<td>30</td>
<td align="right">52</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$1.1</td>
<td>$1.0</td>
<td>$1.07</td>
<td>$88.00</td>
<td>$82.7K</td>
<td>0</td>
<td align="right">853</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$3.2</td>
<td>$3.1</td>
<td>$3.1</td>
<td>$80.00</td>
<td>$46.5K</td>
<td>1.9K</td>
<td align="right">211</td>
</tr>
<tr>
<td>DXCM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$4.5</td>
<td>$4.4</td>
<td>$4.4</td>
<td>$78.00</td>
<td>$42.2K</td>
<td>0</td>
<td align="right">107</td>
</tr>
<tr>
<td>DXCM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$21.3</td>
<td>$20.9</td>
<td>$20.9</td>
<td>$75.00</td>
<td>$41.8K</td>
<td>24</td>
<td align="right">0</td>
</tr>
</tbody>
</table>

<h3>About DexCom</h3>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Having examined the options trading patterns of DexCom, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of DexCom</h3>
<ul>
<li>With a trading volume of 2,245,122, the price of DXCM is up by 1.15%, reaching $76.75.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 80 days from now.</li>
</ul>
<h3>What The Experts Say On DexCom</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $96.6.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has decided to maintain their Outperform rating on DexCom, which currently sits at a price target of $86. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for DexCom, targeting a price of $115. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on DexCom, which currently sits at a price target of $105. 
&#x2A; Consistent in their evaluation, an analyst from Wells Fargo keeps a Overweight rating on DexCom with a target price of $90. 
&#x2A; An analyst from Leerink Partners has decided to maintain their Outperform rating on DexCom, which currently sits at a price target of $87. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest DexCom options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

DexCom's Options Frenzy: What You Need to Know

Billionaire investor Chase Coleman's hedge fund, Tiger Global Management, filed its latest <a href="https://www.sec.gov/Archives/edgar/data/1167483/000091957424006690/xslForm13F_X02/infotable.xml">Form 13F</a> on Thursday and disclosed its trading activity from the prior quarter. Here's a look at Tiger Global's <a href="https://www.benzinga.com/opinion/24/08/40422936/steal-these-two-stock-ideas-from-the-best-investors-in-the-world">portfolio changes.&nbsp;</a>
The Details: Tiger Global has $23.439 billion in assets under management and made no changes to its top five holdings:&nbsp;
<ul>
<li>Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) </li>
<li>Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) </li>
<li>Alphabet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) </li>
<li>Apollo Global Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) </li>
<li>Sea Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SE#NYSE">SE</a>) </li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
New Positions: Tiger Global opened three new positions including a $801.3 million stake in Flutter Entertainment Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>), the parent company of FanDuel. The fund also opened a $201.4 million position in Sherwin-Williams Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) and a $48.9 million position in South Korean e-commerce platform Coupang, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPNG#NYSE">CPNG</a>). 
Notable Trades: Tiger Global added 564,090 shares of Taiwan Semiconductor Manufacturing Company Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) to its portfolio, bringing its total number of shares owned to 3,634,980. The fund also increased its stake in Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) by 195,714 shares, bringing its current holdings to 5,839,256 shares valued at $897.5 million. 
Closed Positions: The hedge fund closed out its positions in Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) and DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) 
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Image created using artificial intelligence via MidJourney.

Tiger Global Hedge Fund Buys Flutter Entertainment Stock, Sells DexCom

In the latest quarter, 12 analysts provided ratings for DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>), showcasing a mix of bullish and bearish perspectives.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated DexCom and provided 12-month price targets. The average target is $97.67, accompanied by a high estimate of $120.00 and a low estimate of $82.00. Observing a downward trend, the current average is 2.74% lower than the prior average price target of $100.42. 
<img src="https://www.benzinga.com/files/images/story/2024/1729882856_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of DexCom among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee Hambright</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Strong Buy</td>
<td>$99.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Steven Lichtman</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Robbie Marcus</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$120.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Jeff Johnson</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$82.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Matt Miksic</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$113.00</td>
<td>$138.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to DexCom. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of DexCom compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for DexCom's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into DexCom's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/DXCM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on DexCom analyst ratings.</a>
<h2>Delving into DexCom's Background</h2>
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
<h3>Breaking Down DexCom's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: DexCom displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 15.26%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: DexCom's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 14.29%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 6.13%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): DexCom's ROA excels beyond industry benchmarks, reaching 2.16%. This signifies efficient management of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.07, DexCom faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For DexCom's Future

DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) reported better-than-expected third-quarter <a href="https://www.benzinga.com/news/earnings/24/10/41532118/dexcom-stock-drops-after-q3-results-announces-c-suite-transition#:~:text=The%20Details%3A%20DexCom%20reported%20quarterly,the%20same%20period%20last%20year.">results on Thursday</a>. 
DexCom reported quarterly earnings of 45 cents per share, which beat the analyst consensus estimate of 43 cents. Quarterly revenue came in at $994.2 million which beat the analyst consensus estimate of $990.71 million and is an increase over sales of $975 million from the same period last year.
DexCom also announced Teri Lawver, executive vice president and chief commercial officer, will retire at the end of the year. Lawver will continue as a special advisor to Dexcom through early 2025 and Kevin Sayer, chairman, president and CEO, will assume leadership of the commercial organization as the company conducts a global search for a new chief commercial officer.
DexCom shares fell 1.6% to trade at $73.68 on Friday.
These analysts made changes to their price targets on DexCom following earnings announcement.
<ul>
<li>Wells Fargo analyst Larry Biegelsen maintained DexCom with an Overweight and raised the price target from $80 to $90.</li>
<li>Leerink Partners analyst Mike Kratky maintained DexCom with an Outperform and lowered the price target from $90 to $87.</li>
<li>JP Morgan analyst Robbie Marcus maintained the stock with a Neutral and raised the price target from $75 to $85.</li>
<li>Oppenheimer analyst Steven Lichtman maintained DexCom with an Outperform and lowered the price target from $115 to $105.</li>
<li>RBC Capital analyst Shagun Singh maintained the stock with an Outperform and lowered the price target from $120 to $115.</li>
<li>Bernstein analyst Lee Hambright maintained DexCom with an Outperform and raised the price target from $82 to $86.</li>
<li>Raymond James analyst Jayson Bedford maintained DexCom with a Strong Buy and lowered the price target from $115 to $99.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41543872/how-to-earn-500-a-month-from-waste-management-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Waste Management Stock Ahead Of Q3 Earnings</a></li>
</ul>

These Analysts Revise Their Forecasts On DexCom Following Q3 Results

Bernstein analyst Lee Hambright maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Outperform and raises the price target from $82 to $86.

Bernstein Maintains Outperform on DexCom, Raises Price Target to $86

Raymond James analyst Jayson Bedford maintains DexCom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) with a Strong Buy and lowers the price target from $115 to $99.

Raymond James Maintains Strong Buy on DexCom, Lowers Price Target to $99

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on LifeMD (LFMD – Research Report) and Dexcom (DXCM – R...

Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Dexcom (DXCM)

Abbott in settlement with DexCom over continuous glucose monitors

In a regulatory filing, DexCom (DXCM) stated: "As previously disclosed, DexCom has been involved in global patent litigation with Abbott (ABT) Diab...

DexCom, Abbott agree to settle patent litigation

Wall Street Breakfast Podcast: Biden To Rule On US Steel Takeover

Wells Fargo notes Abbott (ABT) and DexCom (DXCM) have disclosed that on December 20, they settled and entered into a cross-license agreement to res...

Abbott, DexCom settlement 'not a complete surprise,' says Wells Fargo

Carillon Eagle Mid Cap Growth Fund Q3 2024 Commentary

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom (DXCM – Research Report) on December 27 and set a price target of $94.00. The...

Wells Fargo Remains a Buy on Dexcom (DXCM)

Wells Fargo spotlights 31 names it believes 'offer above-average growth potential'

In a report released on January 6, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Dexcom (DXCM – Research Report), with a price ta...

RBC Capital Reaffirms Their Buy Rating on Dexcom (DXCM)

Bernstein raised the firm's price target on DexCom (DXCM) to $89 from $86 and keeps an Outperform rating on the shares as part of a broader researc...

DexCom price target raised to $89 from $86 at Bernstein

ABNB

AMZN

BURL

CELH

CPAY

CRWD

ENTG

FICO

ILMN

KEYS

LFMD

NPSCY

ORLY

PAYC

PLNT

SBAC

SNPS

TREX

TSLA

UBER

WDAY

Screenshot 2024-12-03 at 7.43.04 PM

GCTK

Driving Innovation In Diabetes Management: Glucotrack Begins Enrollment For Human Clinical Trials For Its Implantable Continuous Blood Glucose Monitor

Screenshot 2024-10-03 at 5.30.47 PM

SENS

Expanding Continuous Glucose Monitoring Options: How Glucotrack Is Helping Usher In The Next Generation Of Diabetes Care Technology

Screenshot 2024-08-23 at 5.43.44 PM

Poster Presentations, Upcoming Human Trials, Recently Secured Funding And More: Glucotrack&#39;s Plans To Transform The Continuous Glucose Monitoring Market

Movers & Shakers

Continuous Blood Glucose Monitoring Can Materially Improve The Quality Of Life For People With Diabetes – Glucotrack Wants To Make It Easier

Legal

Press Releases

DEADLINE ALERT for SPIR, OFIX, and DXCM: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DexCom

DEXCOM ALERT: Bragar Eagel & Squire, P.C. is Investigating DexCom, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Dexcom Reports Third Quarter 2024 Financial Results

Dexcom Helps People With Diabetes Take the First Step to Discover What They're Made Of on World Diabetes Day

Dexcom and ŌURA Announce Strategic Partnership

Dexcom Launches the First Generative AI Platform in Glucose Biosensing

DEXCOM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM

Comments

DexCom

매도 수량

DexCom (NASDAQ:DXCM) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌